Zombie lies eat my brain

Hydroxychloroquine flunks Phase III trial in mild-to-moderate Covid-19The study adds to the growing body of evidence that the drug, promoted early in the pandemic by President Trump, is ineffective, despite its getting a briefly renewed lease on life earlier this month thanks to a retrospective analysis.  Results of new clinical trial published late last week have found that hydroxychloroquine – the malaria and autoimmune disease drug that President Donald Trump promoted as a potential “game changer” early in the Covid-19 pandemic – not only failed to improve outcomes in those with mild-to-moderate disease, but also produced a higher rate of cardiac and liver side effects. . . .The results add to the growing body of evidence not supporting treatment of Covid-19 with hydroxychloroquine, an analogue of chloroquine, which has also been explored without success in Covid-19. Last month, the Food and Drug Administration revoked an emergency use authorization that it had granted to the drug in late March, a move that had been criticized as motivated more by politics than by science.The drug nevertheless saw a briefly renewed lease on life earlier this month when researchers at the Henry Ford Health System in Detroitpublished a retrospective analysis of 2,541 hospitalized Covid-19 patients in the International Journal of Infectious Diseases showing that 13% of those treated with the drug died, compared with 26.4% of those who did not receive it. However, while sever...
Source: Stayin' Alive - Category: American Health Source Type: blogs